Stay updated with breaking news from Kima Papp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Psoriasis Area and Severity Index, or PASI, was developed in the 1970s as a tool for assessing the severity of psoriatic lesions for the purpose...
NEW ORLEANS — Izokibep, a novel interleukin-17 inhibitor, has shown dramatic responses in hidradenitis suppurativa treatment in an early phase 2 study, according to a speaker at the American Academy of Dermatology Annual Meeting.“[Hidradenitis suppurativa (HS)] is a horrible, horrible disease with a high disease burden. It’s extremely disruptive to anyone’s personal
A small molecule IL-17A inhibitor, izokibep has additionally shown efficacy in treating psoriatic arthritis—and will now be reviewed in a phase 3 HS trial.
- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study
EQS-News: Can-Fite Biopharma This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers 31.10.2022 / 14:15 CET/CEST The issuer is solely responsible